Seeking Alpha

First patient enrolled in BrainStorm ALS Phase 2

  • The first patient has been enrolled in BrainStorm Cell Therapeutics' (BCLI) Phase 2 ALS clinical trial at Mass General Hospital in Boston. The study will evaluate the safety and efficacy of the transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors ("MSC-NTF" or "NurOwn") in 48 ALS patients at three hospitals (Mass General, UMass Hospital in Worcester and the Mayo Clinic in Rochester, NY).
  • NurOwn is an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into MSC-NTF cells. These neuron-supporting cells secrete elevated levels of neurotrophic factors that protect existing motor neurons, promote motor neuron growth and re-establish nerve-muscle interaction.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: